Strong sales growth despite significant COVID-19 impact in prior year
Net sales (in million CHF)
+4.7%
3'835
4'014
+6.4%
1'908
2'030
+3.6%
2'831
2'933
Galenica Group
Products & Care
Logistics & IT
Growth without
2021
2022
+7.1%
+9.6%
+5.6%
COVID-19 initiatives 1)
1 Impact of COVID-19 initiatives includes net sales of PCR tests, Rapid Antigen tests, self-tests as well as vaccinations
19 January 2023
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Galenica AG published this content on 19 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 January 2023 05:59:02 UTC.
Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
GALENICA AG 
